Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Ananth Shankar, Janis Hayward, Amy Kirkwood, Keith McCarthy, Martin Hewitt, Bruce Morland, Stephen Daw
文献索引:Br. J. Haematol. 165(4) , 534-44, (2014)
全文:HTML全文
摘要
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [HL] after a primary chemotherapy alone treatment strategy. Between 2000 and 2005, 80 children with relapsed [n = 69] or primary refractory [n = 11] HL were treated on a standardized treatment protocol of 4-6 cycles of EPIC [etoposide, prednisolone, ifosfamide and cisplatin] chemotherapy. Radiotherapy was recommended to all relapsed sites. High dose therapy with stem cell rescue [SCT] was recommended for patients with poor response. The 5-year overall survival [OS] and progression-free survival from relapse was 75·8% [64·8-83·9] and 59·9% [48·3-69·7] respectively. Duration of first remission was strongly associated with OS; risk of death was decreased by 53% [Hazard ratio (HR): 0·47, 95% confidence interval (CI): 0·19-1·18] for those with a time from end of treatment to relapse of 3-12 months (compared to <3 months) and reduced by 80% (HR 0·20, 95% CI: 0·04-0·90) for those >12 months after end of treatment. Other poor prognostic factors included advanced stage disease at relapse and B symptoms at first diagnosis. The most important factor associated with salvage failure was time to relapse. Survival outcome in children with primary refractory HL is poor.© 2014 John Wiley & Sons Ltd.
相关化合物
相关文献:
2014-12-01
[Eur. J. Cancer 50(18) , 3243-61, (2014)]
2015-02-01
[Mol. Cell Biochem. 400(1-2) , 41-50, (2015)]
2014-12-01
[Biochim. Biophys. Acta 1841(12) , 1672-82, (2015)]
2015-02-01
[Fundam. Clin. Pharmacol. 29(1) , 62-71, (2015)]
2014-12-01
[Eur. J. Nutr. 53(8) , 1645-57, (2014)]